» Articles » PMID: 12223121

Progesterone Receptors - Animal Models and Cell Signaling in Breast Cancer: Role of Steroid Receptor Coactivators and Corepressors of Progesterone Receptors in Breast Cancer

Overview
Specialty Oncology
Date 2002 Sep 12
PMID 12223121
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Progesterone, an ovarian steroid hormone, plays a key role in the development and function of the mammary gland, as it also does in the uterus and the ovary. The action of progesterone is mediated through its intracellular cognate receptor, the progesterone receptor (PR), which functions as a transcription factor that regulates gene expression. As with other nuclear receptors, coregulators (coactivators and corepressors) recruited by the liganded or unliganded PR, either to enhance or to suppress transcription activity, modulate the function of the PR. Mutation or aberrant expression of the coregulators might thus affect the normal function of the PR and hence disrupt the normal development of the mammary gland, which may lead to breast cancer.

Citing Articles

Receptor tyrosine kinases and steroid hormone receptors in breast cancer: .

Teklemariam A, Muche Z, Agidew M, Mulu A, Zewde E, Baye N Metabol Open. 2024; 24:100324.

PMID: 39493231 PMC: 11530601. DOI: 10.1016/j.metop.2024.100324.


Molecular characterization of breast cancer cell pools with normal or reduced ability to respond to progesterone: a study based on RNA-seq.

Bustamante Eduardo M, Keller I, Schuster N, Aebi S, Jaggi R J Genet Eng Biotechnol. 2023; 21(1):81.

PMID: 37550554 PMC: 10406740. DOI: 10.1186/s43141-023-00541-6.


Proteome-wide Profiling of Asymmetric Dimethylated Arginine in Human Breast Tumors.

Ma M, Liu F, Miles H, Kim E, Fields L, Xu W J Am Soc Mass Spectrom. 2023; 34(8):1692-1700.

PMID: 37463068 PMC: 10726702. DOI: 10.1021/jasms.3c00154.


HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes.

Hart V, Gautrey H, Kirby J, Tyson-Capper A Oncotarget. 2020; 11(46):4338-4357.

PMID: 33245725 PMC: 7679030. DOI: 10.18632/oncotarget.27789.


Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast Cancer.

Takeiwa T, Ikeda K, Mitobe Y, Horie-Inoue K, Inoue S Cancers (Basel). 2020; 12(6).

PMID: 32486413 PMC: 7353012. DOI: 10.3390/cancers12061424.


References
1.
Sivaraman L, Nawaz Z, Medina D, Conneely O, OMalley B . The dual function steroid receptor coactivator/ubiquitin protein-ligase integrator E6-AP is overexpressed in mouse mammary tumorigenesis. Breast Cancer Res Treat. 2000; 62(3):185-95. DOI: 10.1023/a:1006410111706. View

2.
Voegel J, Heine M, Zechel C, Chambon P, Gronemeyer H . TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 1996; 15(14):3667-75. PMC: 452006. View

3.
Xu J, Qiu Y, Demayo F, Tsai S, Tsai M, OMalley B . Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science. 1998; 279(5358):1922-5. DOI: 10.1126/science.279.5358.1922. View

4.
Rowan B, OMalley B . Progesterone receptor coactivators. Steroids. 2000; 65(10-11):545-9. DOI: 10.1016/s0039-128x(00)00112-4. View

5.
Zhou D, Quach K, Yang C, Lee S, Pohajdak B, Chen S . PNRC: a proline-rich nuclear receptor coregulatory protein that modulates transcriptional activation of multiple nuclear receptors including orphan receptors SF1 (steroidogenic factor 1) and ERRalpha1 (estrogen related receptor alpha-1). Mol Endocrinol. 2000; 14(7):986-98. DOI: 10.1210/mend.14.7.0480. View